Cancer Risk Assessment Method for Urological and Gastrointestinal Cancers Using 5-Aminolevulinic Acid (5-ALA)

Inoue Keiji0 sites90 target enrollmentAugust 30, 2022

Overview

No summary available.

Registry

who.int

Start Date

August 30, 2022

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Inoue Keiji

•Urologic and gastrointestinal cancer patients: Group 1
•All of the following criteria must be met in order to participate in this study
•(i) Cancer patients aged 20 years or older (regardless of gender)
•(ii) Patients diagnosed with the cancer types in this study (prostate, renal, bladder, or colorectal cancer) and scheduled for robotic\-assisted laparoscopic surgery or laparoscopic surgery..
•(iii) Patients who have not received high\-concentration vitamin C therapy, 5\-ALA combined treatment (e.g., heat, radiation, or other phototherapy) in the period one month prior to urine collection.
•(iv) Patients who can stop taking supplements, drinking alcohol, smoking, etc. on the day of urine
•(v) Patients who have given written consent to participate in this study.
•Cancer\-free subjects: Group 2
•All of the following criteria must be met in order to
•participate in this study

•Urologic and gastrointestinal cancer patients: Group 1
•If any one of the following criteria applies to you, you are not eligible to participate in this study.
•(i) Patients with a history of hypersensitivity to 5\-ALA or porphyria
•(ii) Patients with a history or diagnosis of porphyria
•(iii) Patients who must be administered drugs known to cause photosensitivity or foods containing S
•t. John's Wort (St. John's wort) on the day of urine collection.
•(iv) Pregnant women or patients of childbearing potential or lactating mothers.
•(v) Patients with serious cardiovascular, pulmonary, hepatic, or renal disease, who are undergoing tre
•atment or are at risk for such diseases.
•(vi) Patients participating in other clinical trials